Meeder Asset Management’s Exagen XGN Stock Holding History

Meeder Asset Management’s Portfolio XGN Stock Details XGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-1,351	Closed	-$21K	–	2517
2020 Q1	$21K	Buy	+1,351	New	+$26.8K	﹤0.01%	1233

Other funds holding XGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Meeder Asset Management's XGN Position: Q2 2020 in Review

Meeder Asset Management sold out of Exagen (XGN) in Q2 2020, closing a stake of 1,351 shares — an estimated $21K sold.

Meeder Asset Management first reported a position in XGN in Q1 2020 and held it in 1 quarter. The position peaked at $21K in Q1 2020. 34 funds tracked by Wall St. Rank hold XGN as of Q2 2020.

Meeder Asset Management reported no remaining Exagen position as of Q2 2020 after selling out during the quarter.
Meeder Asset Management sold 1,351 Exagen shares in Q2 2020, an estimated $21K.
Meeder Asset Management first reported a position in Exagen in Q1 2020 and held it in 1 quarter.
Meeder Asset Management's Exagen position peaked at $21K in Q1 2020.
34 funds tracked by Wall St. Rank held Exagen as of Q2 2020.

Based on Meeder Asset Management's 13F filing for Q2 2020, filed 11 Aug 2020.